SEC Company Response from INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Feb 10, 2020
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: Feb. 10, 2020 · CIK: 0001055726 · Accession: 0001193125-20-029793
AI Filing Summary & Sentiment
File numbers found in text: 333-236202
Show Raw Text
CORRESP 1 filename1.htm CORRESP February 10, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento RE: Inovio Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 31, 2020 File No. 333-236202 Acceleration Request Requested Date: February 13, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on February 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Jeffrey Libson of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053. Very truly yours, Inovio Pharmaceuticals, Inc. /s/ Peter Kies Peter Kies Chief Financial Officer cc: Brian Leaf, Cooley LLP Jeffrey Libson, Cooley LLP